133 related articles for article (PubMed ID: 2453507)
1. Generation and characterization of peptide-specific antibodies that inhibit von Willebrand factor binding to glycoprotein IIb-IIIa without interacting with other adhesive molecules. Selectivity is conferred by Pro1743 and other amino acid residues adjacent to the sequence Arg1744-Gly1745-Asp1746.
Berliner S; Niiya K; Roberts JR; Houghten RA; Ruggeri ZM
J Biol Chem; 1988 Jun; 263(16):7500-5. PubMed ID: 2453507
[TBL] [Abstract][Full Text] [Related]
2. Multiple epitope specificity of monoclonal antibodies to a single synthetic peptide: use in the characterization of the GP IIb-IIIa binding domain of von Willebrand factor.
Berliner SA; Houghten RA; Roberts JR; Ruggeri ZM
Adv Exp Med Biol; 1990; 281():133-44. PubMed ID: 1715119
[TBL] [Abstract][Full Text] [Related]
3. Generation and characterization of specific antibodies directed to the binding domain of adhesive molecules.
Berliner SA; Roberts JR; Thorn ML; Ruggeri ZM
Pept Res; 1988; 1(2):60-4. PubMed ID: 2485226
[TBL] [Abstract][Full Text] [Related]
4. Anti-idiotypic antibodies against an antibody to the platelet glycoprotein (GP) IIb-IIIa complex mimic GP IIb-IIIa by recognizing fibrinogen.
Abrams CS; Ruggeri ZM; Taub R; Hoxie JA; Nagaswami C; Weisel JW; Shattil SJ
J Biol Chem; 1992 Feb; 267(4):2775-85. PubMed ID: 1370832
[TBL] [Abstract][Full Text] [Related]
5. Evidence that the arg1744 gly1745 asp1746 sequence in the GPIIb-IIIa-binding domain of von Willebrand factor is involved in platelet adhesion and thrombus formation on subendothelium.
Weiss HJ; Hoffmann T; Yoshioka A; Ruggeri ZM
J Lab Clin Med; 1993 Sep; 122(3):324-32. PubMed ID: 8409708
[TBL] [Abstract][Full Text] [Related]
6. Preferential antagonism of the interactions of the integrin alpha IIb beta 3 with immobilized glycoprotein ligands by snake-venom RGD (Arg-Gly-Asp) proteins. Evidence supporting a functional role for the amino acid residues flanking the tripeptide RGD in determining the inhibitory properties of snake-venom RGD proteins.
Lu X; Williams JA; Deadman JJ; Salmon GP; Kakkar VV; Wilkinson JM; Baruch D; Authi KS; Rahman S
Biochem J; 1994 Dec; 304 ( Pt 3)(Pt 3):929-36. PubMed ID: 7529494
[TBL] [Abstract][Full Text] [Related]
7. Epitope mapping by cDNA expression of a monoclonal antibody which inhibits the binding of von Willebrand factor to platelet glycoprotein IIb/IIIa.
Piétu G; Ribba AS; Chérel G; Meyer D
Biochem J; 1992 Jun; 284 ( Pt 3)(Pt 3):711-5. PubMed ID: 1377911
[TBL] [Abstract][Full Text] [Related]
8. Von Willebrand factor promotes endothelial cell adhesion via an Arg-Gly-Asp-dependent mechanism.
Dejana E; Lampugnani MG; Giorgi M; Gaboli M; Federici AB; Ruggeri ZM; Marchisio PC
J Cell Biol; 1989 Jul; 109(1):367-75. PubMed ID: 2545728
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of fibrinogen binding to GP IIb-IIIa by a GP IIIa peptide.
Charo IF; Nannizzi L; Phillips DR; Hsu MA; Scarborough RM
J Biol Chem; 1991 Jan; 266(3):1415-21. PubMed ID: 1703149
[TBL] [Abstract][Full Text] [Related]
10. A monoclonal antibody recognizes a von Willebrand factor domain within the amino-terminal portion of the subunit that modulates the function of the glycoprotein IB- and IIB/IIIA-binding domains.
Tornai I; Arnout J; Deckmyn H; Peerlinck K; Vermylen J
J Clin Invest; 1993 Jan; 91(1):273-82. PubMed ID: 8423224
[TBL] [Abstract][Full Text] [Related]
11. Ca2+-dependent binding of a synthetic Arg-Gly-Asp (RGD) peptide to a single site on the purified platelet glycoprotein IIb-IIIa complex.
Steiner B; Cousot D; Trzeciak A; Gillessen D; Hadváry P
J Biol Chem; 1989 Aug; 264(22):13102-8. PubMed ID: 2753902
[TBL] [Abstract][Full Text] [Related]
12. Adhesive properties of the beta 3 integrins: comparison of GP IIb-IIIa and the vitronectin receptor individually expressed in human melanoma cells.
Kieffer N; Fitzgerald LA; Wolf D; Cheresh DA; Phillips DR
J Cell Biol; 1991 Apr; 113(2):451-61. PubMed ID: 1707057
[TBL] [Abstract][Full Text] [Related]
13. Triflavin, an antiplatelet Arg-Gly-Asp-containing peptide, is a specific antagonist of platelet membrane glycoprotein IIb-IIIa complex.
Huang TF; Sheu JR; Teng CM; Chen SW; Liu CS
J Biochem; 1991 Feb; 109(2):328-34. PubMed ID: 1864844
[TBL] [Abstract][Full Text] [Related]
14. Trigramin: primary structure and its inhibition of von Willebrand factor binding to glycoprotein IIb/IIIa complex on human platelets.
Huang TF; Holt JC; Kirby EP; Niewiarowski S
Biochemistry; 1989 Jan; 28(2):661-6. PubMed ID: 2653425
[TBL] [Abstract][Full Text] [Related]
15. Identification of amino acid residues essential for von Willebrand factor binding to platelet glycoprotein Ib. Charged-to-alanine scanning mutagenesis of the A1 domain of human von Willebrand factor.
Matsushita T; Sadler JE
J Biol Chem; 1995 Jun; 270(22):13406-14. PubMed ID: 7539426
[TBL] [Abstract][Full Text] [Related]
16. The Arg-Gly-Asp (RGD) recognition site of platelet glycoprotein IIb-IIIa on nonactivated platelets is accessible to high-affinity macromolecules.
Tomiyama Y; Tsubakio T; Piotrowicz RS; Kurata Y; Loftus JC; Kunicki TJ
Blood; 1992 May; 79(9):2303-12. PubMed ID: 1373972
[TBL] [Abstract][Full Text] [Related]
17. Structure and function of the von Willebrand factor A1 domain: analysis with monoclonal antibodies reveals distinct binding sites involved in recognition of the platelet membrane glycoprotein Ib-IX-V complex and ristocetin-dependent activation.
De Luca M; Facey DA; Favaloro EJ; Hertzberg MS; Whisstock JC; McNally T; Andrews RK; Berndt MC
Blood; 2000 Jan; 95(1):164-72. PubMed ID: 10607699
[TBL] [Abstract][Full Text] [Related]
18. Selective inactivation of Von Willebrand factor binding to glycoprotein IIb/IIIa and to inhibitor monoclonal antibody 9 by site-directed mutagenesis.
Jumilly AL; Veyradier A; Ribba AS; Meyer D; Girma JP
Hematol J; 2001; 2(3):180-7. PubMed ID: 11920243
[TBL] [Abstract][Full Text] [Related]
19. A modified Arg-Asp-Val (RDV) peptide derived during the synthesis of Arg-Glu-Asp-Val (REDV), a tetrapeptide derived from an alternatively spliced site in fibronectin, inhibits the binding of fibrinogen, fibronectin, von Willebrand factor and vitronectin to activated platelets.
Chen CS; Papayannopoulos IA; Timmons S; Chou SH; Thiagarajan P
Biochim Biophys Acta; 1991 Oct; 1075(3):237-47. PubMed ID: 1720019
[TBL] [Abstract][Full Text] [Related]
20. Arginine-glycine-aspartic acid- and fibrinogen gamma-chain carboxyterminal peptides inhibit platelet adherence to arterial subendothelium at high wall shear rates. An effect dissociable from interference with adhesive protein binding.
Lawrence JB; Kramer WS; McKeown LP; Williams SB; Gralnick HR
J Clin Invest; 1990 Nov; 86(5):1715-22. PubMed ID: 2243140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
